Xin He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xin He has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Saijun Fan
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
3 shared publications Qidong Huo
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
2 shared publications- Tongpeng Yue
Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Inst Radiat Med, Tianjin 300192, Peoples R China
2 shared publications Wenxuan Li
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
2 shared publicationsXinyue Wang
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
2 shared publicationsYinping Dong
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
2 shared publications
Latest Publications
- RetractionOpen Access
- 1 October 2024
- Published by Spandidos Publications in Oncology Reports
- Vol. 52 (6) , 1
[Retracted] hsa‑miR‑212 modulates the radiosensitivity of glioma cells by targeting BRCA1
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that there appeared to be overlapping sections in a pair of the fluorescence reporter assay data panels shown in Fig. 4B; moreover, upon having conducted an independent investigation of the data in this paper in the Editorial Office, one of the data panels shown in this figure was strikingly similar to data that had previously appeared in different form in a paper written by different authors at a different research institute. Owing to the fact that the contentious data in the above article had already been published prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 39: 977‑984, 2018; DOI: 10.3892/or.2017.6156].
- 1 October 2024
- Published by Spandidos Publications in Oncology Reports
- Vol. 52 (6) , 1
RetractionOpen Access[Retracted] hsa‑miR‑212 modulates the radiosensitivity of glioma cells by targeting BRCA1
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that there appeared to be overlapping sections in a pair of the fluorescence reporter assay data panels shown in Fig. 4B; moreover, upon having conducted an independent investigation of the data in this paper in the Editorial Office, one of the data panels shown in this figure was strikingly similar to data that had previously appeared in different form in a paper written by different authors at a different research institute. Owing to the fact that the contentious data in the above article had already been published prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 39: 977‑984, 2018; DOI: 10.3892/or.2017.6156].
- Open Access
- 17 July 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 72, 421-432
Nicotinamide riboside alleviates ionizing radiation-induced intestinal senescence by alleviating oxidative damage and regulating intestinal metabolism
- 17 July 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 72, 421-432
Open AccessNicotinamide riboside alleviates ionizing radiation-induced intestinal senescence by alleviating oxidative damage and regulating intestinal metabolism
- Open Access
- 18 October 2023
- Published by Elsevier in Radiation Medicine and Protection
- Vol. 4 (4) , 221-226
Evaluating a novel protective agent against radiation-induced acute intestinal injury
- 18 October 2023
- Published by Elsevier in Radiation Medicine and Protection
- Vol. 4 (4) , 221-226
Open AccessEvaluating a novel protective agent against radiation-induced acute intestinal injury
- Open Access
- 26 December 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (1) , 60
Structure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme
Protein tyrosine phosphatase non-receptor 12 (PTPN12) is an important protein tyrosine phosphatase involved in regulating cell adhesion and migration as well as tumorigenesis. Here, we solved a crystal structure of the native PTPN12 catalytic domain with the catalytic cysteine (residue 231) in dual conformation (phosphorylated and unphosphorylated). Combined with molecular dynamics simulation data, we concluded that those two conformations represent different states of the protein which are realized during the dephosphorylation reaction. Together with docking and mutagenesis data, our results provide a molecular basis for understanding the catalytic mechanism of PTPN12 and its role in tumorigenesis.
- 26 December 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (1) , 60
Open AccessStructure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme
Protein tyrosine phosphatase non-receptor 12 (PTPN12) is an important protein tyrosine phosphatase involved in regulating cell adhesion and migration as well as tumorigenesis. Here, we solved a crystal structure of the native PTPN12 catalytic domain with the catalytic cysteine (residue 231) in dual conformation (phosphorylated and unphosphorylated). Combined with molecular dynamics simulation data, we concluded that those two conformations represent different states of the protein which are realized during the dephosphorylation reaction. Together with docking and mutagenesis data, our results provide a molecular basis for understanding the catalytic mechanism of PTPN12 and its role in tumorigenesis.
- RetractedOpen Access
- 15 December 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 39 (3) , 977-984
hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1
Radioresistance remains a major challenge in the treatment of glioma, and the response of patients to radiotherapy varies considerably. MicroRNAs (miRNAs) are involved in various biological processes. The purpose of the present study was to investigate miRNAs involved in the response to radiation in glioma cell lines. Total RNA was isolated from human glioma U251 cells 30 min after -ray exposure and hybridized to an miRNA chip array. miRNA expression profiles were analyzed by quantitative real-time PCR. pcDNA3/EGFP-miR-212 mimic transfection was used to verify the function of miR-212 in colony formation tests, and the effect of miR-212 overexpression on U251 cells was examined by western blot analysis of apoptosis-related proteins (Bcl-2, Bax, caspase-3 and cytochrome c). The target genes of miR-212 were predicted using bioinformatic tools including miRNA databases, and breast cancer susceptibility gene 1 (BRCA1) was selected for further confirmation by EGFP fluorescence reporter and loss- and gain-of-function assays. Of the 16 candidate miRNAs showing altered expression, five were assessed by real-time PCR; miR-212 was identified as contributing to the radioresistance of glioma cells and was shown to attenuate radiation-induced apoptosis. miR-212 negatively regulated BRCA1 expression by interacting with its 3-untranslated region, suggesting a correlation between BRCA1 expression and radiosensitivity in glioma cells. U-118MG and SHG-44 cell lines were used to confirm these observations. The response of glioma cells to radiation involves the miR-212-mediated modulation of BRCA1 gene expression, suggesting that the miR-212/BRCA1 axis may play a potential role in the radiotherapy of gliomas.
- 15 December 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 39 (3) , 977-984
RetractedOpen Accesshsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1
Radioresistance remains a major challenge in the treatment of glioma, and the response of patients to radiotherapy varies considerably. MicroRNAs (miRNAs) are involved in various biological processes. The purpose of the present study was to investigate miRNAs involved in the response to radiation in glioma cell lines. Total RNA was isolated from human glioma U251 cells 30 min after -ray exposure and hybridized to an miRNA chip array. miRNA expression profiles were analyzed by quantitative real-time PCR. pcDNA3/EGFP-miR-212 mimic transfection was used to verify the function of miR-212 in colony formation tests, and the effect of miR-212 overexpression on U251 cells was examined by western blot analysis of apoptosis-related proteins (Bcl-2, Bax, caspase-3 and cytochrome c). The target genes of miR-212 were predicted using bioinformatic tools including miRNA databases, and breast cancer susceptibility gene 1 (BRCA1) was selected for further confirmation by EGFP fluorescence reporter and loss- and gain-of-function assays. Of the 16 candidate miRNAs showing altered expression, five were assessed by real-time PCR; miR-212 was identified as contributing to the radioresistance of glioma cells and was shown to attenuate radiation-induced apoptosis. miR-212 negatively regulated BRCA1 expression by interacting with its 3-untranslated region, suggesting a correlation between BRCA1 expression and radiosensitivity in glioma cells. U-118MG and SHG-44 cell lines were used to confirm these observations. The response of glioma cells to radiation involves the miR-212-mediated modulation of BRCA1 gene expression, suggesting that the miR-212/BRCA1 axis may play a potential role in the radiotherapy of gliomas.
- Open Access
- 26 April 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (37) , 22640-22648
Evaluation of the protective effects of 13 traditional Chinese medicine compounds on ionizing radiation injury: bupleurum, shenmai, and breviscapine as candidate radioprotectors
Background: Drugs are being sought that are effective as radioprotection for use in both planned and unplanned radiation exposure. Traditional Chinese medicines have been used successfully for the treatment of free radical-mediated diseases and therefore we expected that exploring such agents could yield an effective radioprotector. We therefore evaluated the radioprotective effects of 13 traditional Chinese medicine compounds (TCMCs) against ionizing radiation damage. Materials and methods: TCMCs were tested in vitro on human kidney 293T cells treated with 0, 2, 4, 6, 8 or 10 Gy irradiation for their ability to promote cell survival. Mice were subjected to a sub-lethal (4 Gy), lethal (7 Gy) or supra-lethal (13 Gy) dose of total-body irradiation (TBI) and TCMCs were tested for their ability to influence survival and hemopoietic function. Results: Of the 13 TCMCs tested, five including bupleurum, shenmai, and breviscapine, promoted survival of 293T cells. bupleurum, shenmai, and breviscapine also prolonged survival times of mice treated with supra-lethal and lethal TBI doses. As expected of an effective radioprotector, they also ameliorated bone marrow suppression, reducing the decrease in bone marrow cells after sub-lethal TBI, and they attenuated the TBI-induced reduction in granulocyte-macrophage colony-forming units. Conclusion: This investigation of TCMCs in vitro and in vivo identified bupleurum, shenmai, and breviscapine as having characteristics consistent with radioprotective agents. Further investigation to identify the bioactive components responsible for the radioprotective effect of these compounds is now required.
- 26 April 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (37) , 22640-22648
Open AccessEvaluation of the protective effects of 13 traditional Chinese medicine compounds on ionizing radiation injury: bupleurum, shenmai, and breviscapine as candidate radioprotectors
Background: Drugs are being sought that are effective as radioprotection for use in both planned and unplanned radiation exposure. Traditional Chinese medicines have been used successfully for the treatment of free radical-mediated diseases and therefore we expected that exploring such agents could yield an effective radioprotector. We therefore evaluated the radioprotective effects of 13 traditional Chinese medicine compounds (TCMCs) against ionizing radiation damage. Materials and methods: TCMCs were tested in vitro on human kidney 293T cells treated with 0, 2, 4, 6, 8 or 10 Gy irradiation for their ability to promote cell survival. Mice were subjected to a sub-lethal (4 Gy), lethal (7 Gy) or supra-lethal (13 Gy) dose of total-body irradiation (TBI) and TCMCs were tested for their ability to influence survival and hemopoietic function. Results: Of the 13 TCMCs tested, five including bupleurum, shenmai, and breviscapine, promoted survival of 293T cells. bupleurum, shenmai, and breviscapine also prolonged survival times of mice treated with supra-lethal and lethal TBI doses. As expected of an effective radioprotector, they also ameliorated bone marrow suppression, reducing the decrease in bone marrow cells after sub-lethal TBI, and they attenuated the TBI-induced reduction in granulocyte-macrophage colony-forming units. Conclusion: This investigation of TCMCs in vitro and in vivo identified bupleurum, shenmai, and breviscapine as having characteristics consistent with radioprotective agents. Further investigation to identify the bioactive components responsible for the radioprotective effect of these compounds is now required.
- Open Access
- 1 March 2014
- Vol. 17 (3) , 189-196
99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究
肺癌是一种死亡率极高的恶性肿瘤,针对肺癌的早期诊断和治疗有着重要的意义和价值,本研究旨在探讨羰基锝法标记的肿瘤抑素T7肽用作裸鼠肺癌早期显像剂的初步研究。 采用羰基锝法标记T7肽,薄层色谱法检测99mTc-T7的放化纯度与稳定性,丙酮作展开系统。测定99mTc-T7与NCI-H157细胞的亲和力。研究99mTc-T7于0.5 h、1 h、2 h、4 h、8 h在荷人非小细胞肺腺癌裸鼠体内的生物分布特性,并计算肿瘤(T)与非肿瘤组织(NT)放射性比值。 99mTc对T7肽标记率高,放化纯度达90%以上,不需进一步纯化,体外稳定性好。99mTc-T7与NCI-H157细胞的平衡解离常数为196.1 nM。99mTc-T7在裸鼠体内主要通过内脏器官代谢,血液清除较快,在肿瘤部位有一定程度聚集,肿瘤/肌肉比值随时间延长而增加,可达到5以上,在4 h-8 h之间取值较为理想。99mTc-T7在肺内存在一过性聚集。 99mTc-T7制备方法简便,标记率高,稳定性好,并能在肺癌肿瘤部位聚集,有望用作肺癌SPECT/CT显像剂。
- 1 March 2014
- Vol. 17 (3) , 189-196
Open Access99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究
肺癌是一种死亡率极高的恶性肿瘤,针对肺癌的早期诊断和治疗有着重要的意义和价值,本研究旨在探讨羰基锝法标记的肿瘤抑素T7肽用作裸鼠肺癌早期显像剂的初步研究。 采用羰基锝法标记T7肽,薄层色谱法检测99mTc-T7的放化纯度与稳定性,丙酮作展开系统。测定99mTc-T7与NCI-H157细胞的亲和力。研究99mTc-T7于0.5 h、1 h、2 h、4 h、8 h在荷人非小细胞肺腺癌裸鼠体内的生物分布特性,并计算肿瘤(T)与非肿瘤组织(NT)放射性比值。 99mTc对T7肽标记率高,放化纯度达90%以上,不需进一步纯化,体外稳定性好。99mTc-T7与NCI-H157细胞的平衡解离常数为196.1 nM。99mTc-T7在裸鼠体内主要通过内脏器官代谢,血液清除较快,在肿瘤部位有一定程度聚集,肿瘤/肌肉比值随时间延长而增加,可达到5以上,在4 h-8 h之间取值较为理想。99mTc-T7在肺内存在一过性聚集。 99mTc-T7制备方法简便,标记率高,稳定性好,并能在肺癌肿瘤部位聚集,有望用作肺癌SPECT/CT显像剂。